Why Is Rising Chronic Disease Prevalence Driving the Global Digital Pathology Market?

Market Overview

The global digital pathology market size was valued at USD 1,022.14 Million in 2024 and is projected to reach USD 2,320.06 Million by 2033, exhibiting a CAGR of 8.54% during 2025-2033. North America dominates with over 40.7% market share in 2024. Key growth drivers include the rising demand for advanced diagnostic tools, increasing chronic disease prevalence, technological advances in AI, healthcare digitization, and supportive regulatory frameworks.

Study Assumption Years
• Base Year: 2024
• Historical Year/Period: 2019-2024
• Forecast Year/Period: 2025-2033

Market Key Takeaways
• Current Market Size: USD 1,022.14 Million in 2024
• CAGR: 8.54% during 2025-2033
• Forecast Period: 2025-2033
• North America accounted for over 40.7% market share in 2024, driven by high-tech healthcare infrastructure and significant investments in healthcare IT.
• The human pathology segment leads with about 62.2% market share in 2024, due to its critical role in disease diagnosis.
• Scanners dominate the product segment, essential for digitizing histopathological slides.
• The academic and research institutes end-user segment holds around 45.7% market share due to its use in education and research.
• The on-premises delivery model is preferred for data security and control by large institutions.

Request for a Free Sample Report: https://www.imarcgroup.com/digital-pathology-market/requestsample

Market Growth Factors

The digital pathology market is growing due to an increase in the demand for advanced diagnostic methods. The rise in prevalence of chronic diseases including cancer is another driving factor. In 2024, it is expected that more than 2 million new cases of cancer and more than 600,000 deaths are expected in the U.S. AI, machine learning, and workflow automation technologies promise improvements in accuracy, earlier detection, and personalized treatment. For example, Roche's systems now contain over 20 machine learning algorithms in their systems, showing the interest in advancing cancer diagnostics.

Imaging technology, imaging software, artificial intelligence and machine learning have helped drive market growth through improvements in imaging quality and analysis automation, as well as predictive diagnostics. Improved health outcomes of 40% and reduced treatment costs of 50% have been estimated. The ability to integrate with electronic medical record systems and laboratory information systems can improve clinical workflow and collaborative medicine, driving global market expansion.

Telepathology, the remote sharing of high-quality slides, is likely to help drive this market further. Its use of high-quality images to augment diagnostic capacity, particularly in remote areas, helps overcome the World Health Organization's predicted shortage of 10 million health care workers worldwide by 2030, thus making it an important area of technology. Digital pathology is scalable and accessible using cloud-based data storage and is a key part of the global healthcare system.

Market Segmentation

By Product:
• Scanners: Lead the market as they digitize histopathological slides, offering high-resolution images for analysis, storage, and sharing, crucial for handling increased pathology sample volumes.
• Software: Not separately described in detail in source.
• Storage Systems: Not separately described in detail in source.
• Communication Systems: Not separately described in detail in source.

By Type:
• Human Pathology: Holds around 62.2% market share in 2024, playing a pivotal role in diagnosing human diseases, with enhanced accuracy due to digital archiving and AI integration.
• Veterinary Pathology: Not separately described in detail in source.

By Delivery Model:
• On-premises: Preferred by healthcare organizations for infrastructure control and data security, enabling compliance with strict regulations.
• Hosted: Not separately described in detail in source.

By Application:
• Training and Education: Facilitates access to digital slides and interactive learning environments.
• Consulting Services: Not separately described in detail in source.
• Intraoperative Consultation: Not separately described in detail in source.
• Routine Diagnostic Consultation Services: Core application involving standard evaluations to diagnose diseases, enhancing efficiency and data retrieval.
• Others: Not separately described in detail in source.

By End-User:
• Pharmaceutical & Biotechnology Companies: Not separately described in detail in source.
• Hospitals and Reference Laboratories: Not separately described in detail in source.
• Academic & Research Institutes: Leads with about 45.7% market share in 2024, supporting comprehensive educational and research programs.

Regional Insights

In 2024, North America dominated the digital pathology market with more than 40.7% of the revenue share. The regional market grew because the area has superior healthcare infrastructure, embraced digital pathology solutions early, and invested more in healthcare IT. Favorable regulations such as numerous FDA approvals and the trend for personalized medicine that requires more detailed testing of tissue samples have driven the leadership.

Recent Developments & News

• March 2025: Royal Philips expanded partnership with Ibex Medical Analytics to enhance AI-enabled digital pathology workflows with Philips IntelliSite Pathology Solution (PIPS) 6.0, showing 37% productivity gains.
• January 2025: Roche obtained FDA 510(k) clearance for VENTANA DP 600 scanner with high throughput capacity to support cancer diagnosis.
• February 2025: Charles River Laboratories and Deciphex extended partnership to integrate Deciphex's Patholytix platform into toxicologic pathology workflows.
• March 2025: Epredia received FDA clearance for E1000 Dx Digital Pathology Solution to enhance cancer diagnostic workflows with high-speed scanning.
• December 2024: Sheba Medical Center and Roche partnered to improve NSCLC diagnostics using AI-powered digital pathology.
• December 2024: Indica Labs joined AWS Partner Network, validating cloud architecture for clinical deployments.
• November 2024: UAB Pathology launched Digital Pathology Transformation Project.
• November 2024: Egypt Healthcare Authority, Roche Diagnostics, and Roche Pharmaceuticals signed an MOU to advance digital pathology in Egypt.
• February 2024: Corista secured Health Canada Class II Medical Device License for its DP3 platform.

Key Players
• DHISTECH
• Apollo Enterprise Imaging
• Corista
• Hamamatsu Photonics
• Huron Digital Pathology
• Indica Labs
• Koninklijke Philips
• Leica Biosystems
• Objective Pathology Services
• Ventana Medical Systems
• Visiopharm
• XIFIN

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

Ask Our Expert & Browse Full Report with TOC & List of Figures: https://www.imarcgroup.com/request?type=report&id=1836&flag=E

Contact Us
IMARC Group,
134 N 4th St. Brooklyn, NY 11249, USA,
Email: sales@imarcgroup.com,
Tel No: (D) +91 120 433 0800,
United States: +1-201971-6302

About Us
IMARC Group is a global management consulting firm that helps the world's most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services.

IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

This release was published on openPR.